Amyris, Inc.
Case Number:
1:23-bk-11131
Court:
Nature of Suit:
Firms
- Archer & Greiner
- ArentFox Schiff
- ArentFox Schiff LLP
- Arnold & Porter
- AXS Law Group
- Ballard Spahr
- Barack Ferrazzano
- Benesch
- Bielli & Klauder
- Blank Rome
- Bragar Eagel
- Buchalter APC
- Cole Schotz
- Connolly Gallagher
- Cross & Simon
- Cyrulnik Fattaruso
- deLeeuw Law
- DLA Piper
- Duane Morris
- Dunlap Bennett
- Foley Hoag
- Fox Rothschild
- Golenbock Eiseman
- Goodwin Procter
- Greenberg Traurig
- Harris Beach PLLC
- Holland & Knight
- Keller & Heckman
- Klehr Harrison
- KTBS Law
- Kudman Trachten
- Landis Rath
- Latham & Watkins
- Lewis Brisbois
- Linebarger Goggan
- Margolis Edelstein
- McCarter & English
- MoloLamken
- Monzack Mersky
- Morris James
- Morris Nichols
- Nixon Peabody
- Ostrager Chong
- Pachulski Stang
- Paul Hastings
- Paul Weiss
- Potter Anderson
- Powell Firm
- Richards Layton
- Rosner Law Group LLC
- Streusand Landon
- Tannenbaum Helpern
- Troutman Pepper
- Tucker Arensberg
- White and Williams
- White & Case
- Womble Bond
- Young Conaway
Companies
- Amyris Inc.
- Ankura Consulting Group LLC
- Cosan Limited
- Dr. Reddy's Laboratories Ltd.
- Givaudan
- Google LLC
- Hearst Corp.
- Intrepid Investment Bankers
- Jefferies Financial Group Inc.
- Microsoft Corp.
- NTT Data Corp.
- Oracle Corp.
- Salesforce.com Inc.
- Sartorius AG
- Sephora SA
- Stretto Inc.
- Thermo Fisher Scientific Inc.
- U.S. Bancorp
Government Agencies
- Massachusetts Department of Revenue
- State of Michigan
- Texas Comptroller of Public Accounts
- U.S. Securities and Exchange Commission
Sectors & Industries:
-
March 18, 2024
Amyris Gets OK To Settle Pot Co.'s $15M Trade Secret Suit
A Delaware bankruptcy judge has approved biotechnology company Amyris' $15.1 million settlement with cannabinoid manufacturer Lavvan, resolving yearslong litigation and arbitration proceedings alleging the debtor misused its then-business partner's trade secrets.
-
February 02, 2024
Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan
A Delaware bankruptcy judge on Friday struck down biotechnology company Amyris Inc.'s plan to shield executives and others from liability using nonconsensual releases as part of its Chapter 11 plan, finding that Amyris can reorganize without relying on the controversial mechanism.
-
January 24, 2024
Amyris Says Claim Releases Needed For Post-Ch. 11 Success
Biotechnology company Amyris Inc. told a Delaware bankruptcy judge on Wednesday it needs to eliminate potential shareholder claims in order to emerge from its Chapter 11 case as a successful company.
-
January 18, 2024
SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan
The U.S. Securities and Exchange Commission and the U.S. Trustee's Office have expressed new concerns about nonconsensual third-party releases in biotechnology company Amyris' Chapter 11 plan, arguing that such releases are only allowed in extraordinary circumstances that were not met by the debtor.
-
January 09, 2024
Amyris Fights Claims In Cannabis IP Row By Defining 'Under'
Biotechnology company Amyris Inc. said Tuesday the word "under" in a contract between it and cannabinoid manufacturer Lavvan supports its effort to quash two claims Lavvan has filed against the debtor, telling a Delaware bankruptcy judge the plain meaning of the preposition bars the claims from going forward.
-
December 20, 2023
Biochemical Co. Amyris OK'd To Sell Celebrity Brands
Bankrupt biochemical company Amyris Inc. can move forward with plans to sell its remaining consumer brands, a Delaware bankruptcy judge ruled Wednesday, after an auction last week raked in winning bids totaling $6 million.
-
December 15, 2023
Amyris Says DIP Lender Will Bid For Remaining Assets
Synthesized biologicals producer Amyris told a Delaware bankruptcy court its debtor-in-possession and prepetition lenders will step in with a stalking horse credit bid for its core assets, unless the Northern California-based company receives a bid greater than $255 million at a Chapter 11 auction in January.
-
December 12, 2023
Amyris Gets OK To Solicit Ch. 11 Plan Votes
A Delaware bankruptcy judge Tuesday allowed biochemical company Amyris Inc. to send its Chapter 11 plan out for a creditor vote, overriding objections tied to the plan's proposed third-party claim releases.
-
December 11, 2023
Amyris Creditors Slam 'Tainted' Ch. 11 Plan
Noteholders and shareholders of bankrupt biochemical company Amyris Inc. have lodged an objection to its Chapter 11 plan and disclosure statement, contending the plan keeps creditors in the dark about the impact of its third-party releases and exemplifies a larger lack of transparency.
-
December 07, 2023
Amyris Files Ch. 11 Plan With $23M Creditor Deal
Biochemical company Amyris Inc. has filed a Chapter 11 plan disclosure statement saying it has reached a deal that could provide more than $23 million to unsecured creditors but that the proceeds of last week's auction of its brand assets were less than expected.